What does the evidence say about Fish Oil Cognition Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Fish Oil Cognition Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Risk of bias was assessed using the Cochrane Risk of Bias tool (RoB 2) and the Newcastle-Ottawa Scale. [Kanaan A (2026); evidence level 1] - Results The findings suggest that consumption of extra virgin olive oil (EVOO), particularly high-phenolic varieties, may be associated with improvements in cognitive domains such as memory, attention, executive function, and global cognition. [Kanaan A (2026); evidence level 1] - However, the evidence is derived from a limited number of heterogeneous studies with relatively small sample sizes. [Kanaan A (2026); evidence level 1] - Background The global increase in life expectancy has led to a higher prevalence of age-related cognitive decline, highlighting the need for effective non-pharmacological interventions. [Kanaan A (2026); evidence level 1] - 9 10 11 12 13 12 From this view, a healthy and balanced diet includes polyunsaturated fatty acids that have been associated with a reduction in the risk of breast and colon cancer [], as well as inflammation in patients suffering from rheumatoid arthritis [] and other inflammatory or degenerative diseases []. [Dimopoulou Maria (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.